AngioDynamics (FRA:UG2) ROCE % : -14.07% (As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is AngioDynamics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AngioDynamics's annualized ROCE % for the quarter that ended in Feb. 2024 was -14.07%.

AngioDynamics ROCE % Historical Data

The historical data trend for AngioDynamics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics ROCE % Chart

AngioDynamics Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

ROCE %

Get a 7-Day Free Trial

-1.40

-25.99

-6.35

-6.38

-11.00

AngioDynamics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															-4.34	-30.55	-8.78	-6.28	-14.07

AngioDynamics ROCE % Calculation

AngioDynamics's annualized ROCE % for the fiscal year that ended in May. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: May. 2023 )		(A: May. 2022 )		(A: May. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: May. 2023 )		(A: May. 2022 )		(A: May. 2023 )
	=	-47.596	/	( ( (522.902 - 70.311)	+	(490.026 - 77.119) )	/ 2 )
	=	-47.596	/	( (452.591	+	412.907)	/ 2 )
	=	-47.596	/	432.749
	=	-11.00 %

AngioDynamics's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-43.004	/	( ( (461.652 - 72.106)	+	(301.129 - 79.605) )	/ 2 )
	=	-43.004	/	( ( 389.546	+	221.524 )	/ 2 )
	=	-43.004	/	305.535
	=	-14.07 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

AngioDynamics (FRA:UG2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AngioDynamics ROCE % Related Terms

Thank you for viewing the detailed overview of AngioDynamics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioDynamics (FRA:UG2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (FRA:UG2) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ANGO:USA UG2:Germany

Address

14 Plaza Drive, Latham, NY, USA, 12110

Website

https://www.angiodynamics.com

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

AngioDynamics (FRA:UG2) Headlines

No Headlines